FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
DUBLIN, Ireland, May 02, 2017 -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarter of 2017 on May 9, 2017 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 9.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena seeks to fundamentally change the course of progressive diseases associated with this biology. The Company’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002/RG7935), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company’s website at www.prothena.com.
Contacts: Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose, Head of Communications 650-922-2405, [email protected]
